Start here if you're new
what it is
It makes oral drugs aimed at obesity and other chronic diseases.
how it gets paid
Last year Structure Therap made n/a in revenue.
what just happened
The quarter printed a -$1.00 EPS loss, and revenue still shows no figure.
At a glance
B+ balance sheet — decent shape, but not bulletproof
-$0.80 fy2025 eps est
$2B fy2026 rev est
1.1 beta
~$4B market cap
xvary composite: 65/100 — average
What they do
It makes oral drugs aimed at obesity and other chronic diseases.
GSBR-1290 is in 2 Phase II trials. Phase II trials → mid-stage human tests → so what: the company still needs proof before revenue exists. You are buying waiting time, not sales.
How they make money
n/a
annual revenue
The products that matter
oral obesity candidate
GSBR-1290
lead asset · $0 current revenue
Positive Phase 2 data showed up to 39 lbs of weight loss. For a $4B company with no commercial revenue, that is the entire near-term investment case.
lead catalyst
gpcr-targeting pipeline
clinical and preclinical programs
pre-revenue · years from approval
There may be platform value here, but the market is not paying for it yet. With 91.8% institutional ownership, the stock is still being priced mainly on the lead obesity readout.
option value
balance-sheet runway
cash-funded development path
$4M debt · B+ balance sheet
Only $4M of long-term debt keeps financing risk lower than many biotechs, but lower is not the same as low when you still have $0 product revenue.
funding matters
Key numbers
$1.00
latest EPS
That is a $1 loss per share in the latest quarter. You own a burn rate, not earnings.
$2B
FY2026 revenue est
's sales forecast is huge for a company with no revenue figure today. That gap is the whole story.
$4M
long-term debt
Debt is tiny at $4M, or 0% of capital. So leverage is not the trap.
1.1
beta
A 1.1 beta means the stock moves a bit more than the market. So volatility is part of the ticket.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 1 — safer than 95% of stocks
- price stability 5 / 100
- long-term debt $4M (0% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for GPCR right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The quarter printed a -$1.00 EPS loss, and revenue still shows no figure.
EDGAR gives you the EPS number. It does not give you sales or gross margin. That leaves you with a company spending before the business is selling.
$1.00
eps
n/a
n/a
n/a
n/a
EPS loss
The -$1.00 loss is the hard fact. It tells you the company is still paying for development before any sales show up.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is clinical failure or underwhelming efficacy for GSBR-1290.
med
Lead-asset concentration
GPCR has no commercial revenue and one program carries most of the valuation burden. If GSBR-1290 stumbles, there is no profitable base business to catch the stock.
Impact: the $4B equity story would need to be rewritten around a much earlier pipeline.
med
Efficacy or tolerability gap versus injectables
An oral pill is convenient. That does not make it competitive by default. Lilly and Novo already own physician attention and patient trust with established injectable GLP-1s.
Impact: even an approved oral drug could earn far less than the current launch math implies.
med
Cash burn and eventual dilution
Q4 2025 EPS of -$0.49 versus a -$0.35 estimate is a reminder that losses can widen while trials get more expensive. A B+ balance sheet helps, but it does not eliminate financing risk.
Impact: future capital raises could dilute you before the science is fully de-risked.
med
Crowded institutional ownership
91.8% institutional ownership signals serious attention, but it also means a lot of holders are waiting on the same catalyst. That is support until it becomes a crowded exit.
Impact: disappointing data can create air pockets in the stock even without a balance-sheet crisis.
With $0 commercial revenue, the current $4B valuation is underwriting future success almost entirely on one lead program.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
Phase 2b obesity trial results
Expected H2 2026. This is the next major proof point for whether GSBR-1290 deserves launch-level revenue expectations.
metric
Quarterly loss trend
Q4 2025 EPS missed by 40%. If losses keep widening, the financing conversation arrives sooner.
competition
New oral GLP-1 data from larger rivals
Any strong oral obesity readout from a better-funded competitor would pressure GPCR's convenience thesis fast.
trend
Consensus revenue optimism
The gap between $0 revenue today and a $2B FY2026 estimate tells you how much future success is already embedded in the story.
Analyst rankings
risk profile
safest 5%
risk rank 1 — lower risk of losing your money than almost any stock.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for GPCR is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$56
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive